This site is intended only for healthcare professionals resident in the Republic of Ireland
P-REALITY X (Palbociclib REAL-world 1st-line ComparaTive Effectiveness Study eXtended) is a comparative effectiveness study of 1st-line IBRANCE in combination with AI vs AI alone1
A total of 2888 patients received IBRANCE in combination with AI or AI alone in the 1st-line setting1
sIPTW was the the primary analysis performed to balance baseline demographic and clinical characteristics, and to adjust for differences in observed potential confounders between the two groups.¹ 1:1 PSM was conducted as a sensitivity analysis.¹
The study included a heterogeneous population in terms of age, performance status and disease site1
Legal Category: S1A
Further information is available upon request
Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
Adverse events should also be reported to Pfizer Medical Information on 1800 633 363
Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.
This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie
This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.
Copyright © 2023 Pfizer Limited. All rights reserved.
The information contained on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland.
I confirm that I am a healthcare professional resident in the Republic of Ireland.*
If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.
PP-UNP-IRL-0176. January 2023